Charles River Laboratories International Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名5/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价189.43。中期看,股价处于上升通道。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Charles River Laboratories International Inc评分
相关信息
行业排名
5 / 404
全市场排名
48 / 4592
所属行业
生物技术与医疗研究
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
18
位分析师
买入
评级
189.428
目标均价
+1.23%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
Charles River Laboratories International Inc亮点
亮点风险
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
公司代码CRL
公司Charles River Laboratories International Inc
CEOFoster (James C)
网址https://www.criver.com/
常见问题
Charles River Laboratories International Inc(CRL)的当前股价是多少?
Charles River Laboratories International Inc(CRL)的当前股价是 198.150。
Charles River Laboratories International Inc的股票代码是什么?
Charles River Laboratories International Inc的股票代码是CRL。
Charles River Laboratories International Inc股票的52周最高点是多少?
Charles River Laboratories International Inc股票的52周最高点是199.660。
Charles River Laboratories International Inc股票的52周最低点是多少?
Charles River Laboratories International Inc股票的52周最低点是91.861。
Charles River Laboratories International Inc的市值是多少?
Charles River Laboratories International Inc的市值是9.75B。
Charles River Laboratories International Inc的净利润是多少?
Charles River Laboratories International Inc的净利润为10.30M。
现在Charles River Laboratories International Inc(CRL)的股票是买入、持有还是卖出?
根据分析师评级,Charles River Laboratories International Inc(CRL)的总体评级为买入,目标价格为189.428。
Charles River Laboratories International Inc(CRL)股票的每股收益(EPS TTM)是多少
Charles River Laboratories International Inc(CRL)股票的每股收益(EPS TTM)是-1.530。